blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3273239

EP3273239 - PROCEDURE OF ANALYSIS OF GLYCOSAMINOGLYCANS, HEPARINS AND THEIR DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  03.09.2021
Database last updated on 28.06.2024
FormerExamination is in progress
Status updated on  22.12.2020
FormerGrant of patent is intended
Status updated on  26.11.2020
FormerExamination is in progress
Status updated on  25.03.2019
FormerRequest for examination was made
Status updated on  20.07.2018
FormerThe application has been published
Status updated on  28.12.2017
Most recent event   Tooltip07.09.2021New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Laboratorios Farmacéuticos Rovi, S.A.
Calle Julián Camarillo 35
28037 Madrid / ES
[2020/52]
Former [2018/04]For all designated states
Laboratorios Farmacéuticos Rovi, S.A.
C/ Julián Camarillo 35
28037 Madrid / ES
Inventor(s)01 / Franco Rodriguez, Guillermo
Laboratorios Farmacéuticos Rovi, S.A.
Calle Julián Camarillo 35
28037 Madrid / ES
02 / Gutierro Aduriz, Ibon
Laboratorios Farmacéuticos Rovi, S.A.
Calle Julián Camarillo 35
28037 Madrid / ES
 [2020/52]
Former [2018/04]01 / Franco, Guillermo
Laboratorios Farmacéuticos Rovi, S.A.
Calle Julián Camarillo 35
28037 Madrid / ES
02 / Gutierro, Ibon
Laboratorios Farmacéuticos Rovi, S.A.
Calle Julián Camarillo 35
28037 Madrid / ES
Representative(s)ABG Intellectual Property Law, S.L.
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid / ES
[N/P]
Former [2018/04]Elzaburu S.L.P.
C/ Miguel Angel, 21
28010 Madrid / ES
Application number, filing date16382350.319.07.2016
[2018/04]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3273239
Date:24.01.2018
Language:EN
[2018/04]
Search report(s)(Supplementary) European search report - dispatched on:EP28.10.2016
ClassificationIPC:G01N33/50, A61K31/727, G01N24/08
[2018/04]
CPC:
G01N24/08 (EP,EA,US); G01N24/087 (EA,US); G01N33/50 (EP,EA,US);
G01R33/4625 (EP,EA,US); G01R33/4633 (EP,EA,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/34]
Former [2018/04]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR ANALYSE VON GLYKOSAMINOGLYKANEN, HEPARINEN UND DEREN DERIVATEN MITTELS KERNMAGNETISCHER RESONANZ[2018/04]
English:PROCEDURE OF ANALYSIS OF GLYCOSAMINOGLYCANS, HEPARINS AND THEIR DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE[2018/04]
French:PROCÉDÉ D'ANALYSE DE GLYCOSAMINOGLYCANES, HÉPARINES ET LEURS DÉRIVÉS PAR RÉSONANCE MAGNÉTIQUE NUCLÉAIRE[2018/04]
Examination proceduredeletedCommunication of intention to grant the patent
19.07.2016Date on which the examining division has become responsible
17.07.2018Amendment by applicant (claims and/or description)
17.07.2018Examination requested  [2018/34]
28.03.2019Despatch of a communication from the examining division (Time limit: M04)
22.07.2019Reply to a communication from the examining division
22.10.2020Cancellation of oral proceeding that was planned for 10.11.2020
10.11.2020Date of oral proceedings (cancelled)
27.11.2020Communication of intention to grant the patent
21.12.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.05.2021Cancellation of oral proceeding that was planned for 19.05.2021
19.05.2021Date of oral proceedings (cancelled)
21.05.2021Despatch of communication that the application is refused, reason: substantive examination [2021/40]
31.05.2021Application refused, date of legal effect [2021/40]
Fees paidRenewal fee
30.07.2018Renewal fee patent year 03
21.06.2019Renewal fee patent year 04
29.06.2020Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.07.202106   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]US7968082  (SHRIVER ZACHARY [US], et al) [I] 1-11 * abstract; table 4; claims 1, 21; examples 1, 2 *;
 [I]  - S.-N. M. C. G. OLIVEIRA ET AL, "Structural and functional analyses of biosimilar enoxaparins available in Brazil", THROMBOSIS AND HAEMOSTASIS, DE, (20140925), vol. 113, no. 1, doi:10.1160/TH14-05-0411, ISSN 0340-6245, pages 53 - 65, XP055312810 [I] 1-11 * abstract; figs. 1, 2; p. 57 *

DOI:   http://dx.doi.org/10.1160/TH14-05-0411
 [I]  - MOURIER PIERRE A J ET AL, "Analytical and statistical comparability of generic enoxaparins from the US market with the originator product", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (20150729), vol. 115, doi:10.1016/J.JPBA.2015.07.038, ISSN 0731-7085, pages 431 - 442, XP029272868 [I] 1-11 * abstract; supplementary data b; figs. 11S-19S *

DOI:   http://dx.doi.org/10.1016/j.jpba.2015.07.038
 [A]  - MICHAEL WEBER ET AL, "Using high-performance quantitative NMR (HP-qNMR ) for certifying traceable and highly accurate purity values of organic reference materials with uncertainties <0.1 %", ACCREDITATION AND QUALITY ASSURANCE, Berlin/Heidelberg, (20130118), vol. 18, no. 2, doi:10.1007/s00769-012-0944-9, ISSN 0949-1775, pages 91 - 98, XP055312811 [A] 1-11 * fig. 4 *

DOI:   http://dx.doi.org/10.1007/s00769-012-0944-9
by applicant   - GANDHI NS; MANCERA RL., "The Structure of Glycosaminoglycans and their Interactions with Proteins", CHEM BIOL DRUG DES, (2008), vol. 72, pages 455 - 482
    - LINHARDT RJ; RICE KG; KIM YS ET AL., "Mapping and quantification of the major oligosaccharides component of heparin", BIOCHEM J, (1988), vol. 254, pages 781 - 787
    - TRAN HAM; GINSBERG JS., Basic principles and clinical practice, LIPPINCOTT WILLIAMS AND WILKINS, (2006), pages 1673 - 1688
    - XU Y. ET AL., "Chemoenzymatic synthesis of homogenous ultra low molecular weight heparins", SCIENCE, (2011), vol. 334, pages 498 - 501
    - BENI S. ET AL., ANAL BIOANAL CHEM, (2011), vol. 399, pages 527 - 539
    - CASU B. ET AL., "Characterization of Sulfation Patterns of Beef and Pig Mucosal Heparins by Nuclear Magnetic Resonance", ARZNEIM.-FORSCH./DRUG RES., (1996), vol. 46, pages 472 - 477, XP008178399
    - KEIRE D.A. ET AL., "Characterization of currently marketed heparin products: composition analysis by 2D-NMR", ANAL. METHODS, (2013), vol. 5, pages 2984 - 2994
    - OZUG J. ET AL., ANAL. BIOANAL. CHEM., (2002), vol. 403, pages 2733 - 2744
    - BISIO A. ET AL., "Structural features of low molecular weight heparins affecting their affinity to antithrombin", THROMB. HEMOST., (2009), vol. 102, doi:doi:10.1160/TH09-02-0081, pages 865 - 873, XP002569660

DOI:   http://dx.doi.org/10.1160/TH09-02-0081
    - GUERRINI M. ET AL., "Low-molecular-weight heparins: structural differentiation by two-dimensional nuclear magnetic resonance spectroscopy", SEMIN THROMB HEMOST, (2007), vol. 33, pages 478 - 487
    - MALZ F.; JANCKE H., "Validation of quantitative NMR", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (2005), vol. 38, pages 813 - 823
    - GLAUSER B.F.; VAIRO B.C.; OLIVEIRA C.P.M.; CINELLI L.P.; PEREIRA M.S.; MOURAO P.A.S., "Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug", J THROMB HAEMOST, (2011), vol. 9, pages 1419 - 1422
    - DESAI U.R.; LINHARDT R.J., "Molecular Weight of Heparin using 13C Nuclear Magnetic Resonance Spectroscopy", J PHARM SCI, (1995), vol. 84, no. 2, pages 212 - 215
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.